SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT00984360

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

A Pilot Trial of Naltrexone for Methamphetamine Addiction - Role of the A118G SNP

The purpose of this study is to determine whether methamphetamine-dependent individuals will use less methamphetamine when treated with naltrexone. The study will also investigate whether individuals with the mu opioid receptor gene variant A118G will use less methamphetamine than individuals without A118G.

NCT00984360 Methamphetamine Dependence
MeSH: Behavior, Addictive
HPO: Addictive behavior

1 Interventions

Name: Naltrexone

Description: 380mg extended-release, given once by intramuscular gluteal injection

Type: Drug

A118G Wild-type


Primary Outcomes

Measure: MA (-) Urine Samples

Time: Twice weekly for 5 weeks

Purpose: Treatment

Allocation: Non-Randomized

Parallel Assignment


There is one SNP

SNPs


1 A118G

A Pilot Trial of Naltrexone for Methamphetamine Addiction - Role of the A118G SNP. --- A118G ---

The study will also investigate whether individuals with the mu opioid receptor gene variant A118G will use less methamphetamine than individuals without A118G. --- A118G ---

The study will also investigate whether individuals with the mu opioid receptor gene variant A118G will use less methamphetamine than individuals without A118G. --- A118G --- --- A118G ---



HPO Nodes


HPO:
Addictive behavior
Genes 17
RARA IRF2BP2 ZBTB16 HTR2A NPM1 NABP1 PML ADH1B BCOR PRKAR1A TBL1XR1 STAT3 STAT5B GABRA2 FIP1L1 NUMA1 ADH1C